Grossi F, Belvedere O, Rosso R
Division of Medical Oncology, University of Udine, Pz.le S. M. Misericordia, 33100 Udine, Italy.
Eur J Cancer. 2003 Jan;39(1):106-11. doi: 10.1016/s0959-8049(02)00239-3.
In this paper, we study the geography of publications in clinical cancer research from 1995 to 1999. A Medline search was performed to retrieve papers in clinical oncology reporting phase I, II and III studies published between 1995 and 1999. Only studies reporting antiblastic chemotherapy have been considered, either alone or in combination with other treatments. For each country, the total number of papers, the total Impact Factor (IF), and the mean IF were determined. Similar calculations were performed to compare the European Union versus North America. 3142 papers were identified. The United States ranks first by number of papers (37.7% share), followed by Italy (9.8%), the United Kingdom (8.5%) and Japan (6.9%). Investigators at European institutions published a higher number of papers compared with their North American colleagues (1362 versus 1288). Still the mean IF of North American papers is higher than the papers with a European address (3.54 versus 3.14). The majority of phase I studies were performed in North America, while most of phase III studies were performed in Europe. These results provide information on the geography of clinical cancer research worldwide, which may reflect the human and economic resources involved in this field.
在本文中，我们研究了1995年至1999年临床癌症研究领域的出版物地理分布情况。通过检索医学文献数据库（Medline）来获取1995年至1999年间发表的临床肿瘤学中报告I期、II期和III期研究的论文。仅考虑报告抗瘤化疗的研究，无论其为单独使用还是与其他治疗方法联合使用。对于每个国家，确定了论文总数、总影响因子（IF）以及平均影响因子。进行了类似的计算以比较欧盟和北美地区的情况。共识别出3142篇论文。美国的论文数量排名第一（占比37.7%），其次是意大利（9.8%）、英国（8.5%）和日本（6.9%）。欧洲机构的研究人员发表的论文数量多于北美同行（1362篇对1288篇）。然而，北美论文的平均影响因子高于欧洲地区的论文（3.54对3.14）。大多数I期研究在北美进行，而大多数III期研究在欧洲进行。这些结果提供了全球临床癌症研究领域的地理分布信息，这可能反映了该领域所涉及的人力和经济资源情况。
